• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Radiopaque microsphere with antibacterial and analgesic effect; from bench to clinic

Research Project

Project/Area Number 20K16806
Research Category

Grant-in-Aid for Early-Career Scientists

Allocation TypeMulti-year Fund
Review Section Basic Section 52040:Radiological sciences-related
Research InstitutionAichi Medical University

Principal Investigator

Narita Akiko  愛知医科大学, 医学部, 助教 (00762080)

Project Period (FY) 2020-04-01 – 2024-03-31
Project Status Completed (Fiscal Year 2023)
Budget Amount *help
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2022: ¥520,000 (Direct Cost: ¥400,000、Indirect Cost: ¥120,000)
Fiscal Year 2021: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2020: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
KeywordsSAP-MS / 血管塞栓術 / 塞栓物質 / 薬剤溶出ビーズ / デリバリーシステム / 薬剤溶出性ビーズ
Outline of Research at the Start

薬剤溶出性ビーズ DEBを用いた塞栓術は局所効果の高い、低毒性の治療とされる。本邦で臨床使用されているDEBに高吸水性ポリマー製球状塞栓物質 SAP-MSがある。SAP-MSは液体を吸収し、膨潤する性質がある。そこで、造影剤と抗生剤や鎮痛剤等の各種薬剤を併せてSAP-MSに吸収させ、視認可能かつ薬剤溶出による種々の作用を有する球状塞栓物質を作成することを着想した。本研究では造影剤/各種薬剤含浸SAP-MSの特性を検討後、動物実験にて治療効果や安全性を評価し、人への臨床応用を目指す。

Outline of Final Research Achievements

Superabsorbent polymer microspheres (SAP-MS) have been clinically used for the treatment as drug-eluting beads. In this study, SAP-MS were suspended in drug solutions: contrast material, antibiotics, analgesics and their mixture, and the characteristics of drug-loaded SAP-MS such as drug absorption, drug release, diameter, and visibility were examined in vitro.
SAP-MS absorbed and released contrast material, antibiotics and analgesics although the degree varied with each drug and drug combination. The diameter of SAP-MS increased for approximately 15 min and then came to an equilibrium. SAP-MS containing contrast material were visible under X-ray imaging.
Although it was possible to create microsphere with visible and various drug-eluting ability, further in vivo studies are needed.

Academic Significance and Societal Importance of the Research Achievements

本研究では視認可能かつ各種薬剤の溶出能を有する球状塞栓物質の作成が可能であった。
抗生剤や鎮痛剤の薬剤溶出が確認できたため、感染の予防や治療、除痛等が可能となり、新たな治療法になりうると考える。また、X線透視下で視認可能であったことは経験によるところが大きいと言われる塞栓の状況判断を容易にし、治療効果と安全性の向上に加え、技術の均一化に寄与すると考える。

Report

(5 results)
  • 2023 Annual Research Report   Final Research Report ( PDF )
  • 2022 Research-status Report
  • 2021 Research-status Report
  • 2020 Research-status Report
  • Research Products

    (3 results)

All 2023 2022

All Journal Article (1 results) (of which Peer Reviewed: 1 results) Presentation (2 results) (of which Int'l Joint Research: 1 results)

  • [Journal Article] In Vitro Characterization of Drug-Loaded Superabsorbent Polymer Microspheres: Absorption and Release Capacity of Contrast Material, Antibiotics and Analgesics2023

    • Author(s)
      Narita Akiko、Nakano Yuta、Okada Hiroaki、Yamamoto Takahiro、Matsunaga Nozomu、Ikeda Shuji、Izumi Yuichiro、Kitagawa Akira、Ota Toyohiro、Suzuki Kojiro
    • Journal Title

      CardioVascular and Interventional Radiology

      Volume: 46 Issue: 11 Pages: 1632-1640

    • DOI

      10.1007/s00270-023-03559-y

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed
  • [Presentation] 高吸水性ポリマー製球状塞栓物質(SAP-MS)における薬剤含浸の特性の検討2023

    • Author(s)
      成田晶子、髙畑恭兵、丸地佑樹、岡田浩章、山本貴浩、松永望、池田秀次、北川晃、泉雄一郎、太田豊裕、鈴木耕次郎
    • Organizer
      第52回日本IVR学会総会
    • Related Report
      2023 Annual Research Report
  • [Presentation] In-vitro Characterization of Drug Eluting Superabsorbent Polymer Microspheres: Absorption and Eluting Capacity of contrast material, antibiotics and/or analgesics2022

    • Author(s)
      Akiko Narita, Hiroaki Okada, Takahiro Yamamoto, Nozomu Matsunaga, Shuji Ikeda, Akira Kitagawa, Yuichiro Izumi,Toyohiro Ota, Kojiro Suzuki
    • Organizer
      RSNA 2022(第108回北米放射線会議)
    • Related Report
      2022 Research-status Report
    • Int'l Joint Research

URL: 

Published: 2020-04-28   Modified: 2025-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi